Prof. Shi Jumei (施菊妹) — Multiple Myeloma, CAR-T & Stem Cell Transplant | Oriental Hospital Shanghai
For international patients with multiple myeloma seeking a physician who combines deep Chinese clinical expertise with firsthand experience at one of the world's premier myeloma centers, Prof. Shi Jumei (施菊妹) offers a rare and compelling profile. With over 30 years of clinical experience in hematology and a period of work at the University of Arkansas for Medical Sciences (UAMS) — home to the Myeloma Center, one of the most influential myeloma programs in the world — Prof. Shi brings an internationally informed perspective to her practice at Oriental Hospital Shanghai.
Specialty Focus
- Multiple myeloma: newly diagnosed, relapsed, and refractory disease
- Novel agent combinations: proteasome inhibitors, IMiDs, anti-CD38 monoclonal antibodies, BCMA-targeted therapies
- Autologous stem cell transplantation (ASCT) for myeloma
- CAR-T cell therapy for relapsed/refractory myeloma
- Plasma cell disorders: smoldering myeloma, MGUS, AL amyloidosis
- Myeloma-related complications: bone disease, renal impairment, peripheral neuropathy management
Academic & Clinical Titles
- Chief Physician & Professor, Department of Hematology, Oriental Hospital Shanghai (Tongji University)
- Vice-Chair, Hematologic Malignancy Translational Medicine Committee, China Anti-Cancer Association (CACA)
- Former clinical fellow/researcher, Myeloma Center, University of Arkansas for Medical Sciences (UAMS), USA
- Over 30 years of clinical experience in hematology with subspecialty focus on plasma cell disorders
The UAMS Connection: Why It Matters
The Myeloma Center at the University of Arkansas for Medical Sciences (UAMS) is one of the most storied and influential myeloma programs in the world. Founded by Dr. Bart Barlogie — a pioneer who developed the Total Therapy approach to myeloma treatment and championed aggressive induction, tandem transplantation, and maintenance strategies — UAMS has trained generations of myeloma specialists and contributed foundational research that has shaped global treatment standards.
Prof. Shi Jumei's experience working at UAMS gives her direct exposure to this tradition of aggressive, evidence-based myeloma management. For international patients — particularly those from the Middle East, Southeast Asia, or other regions where myeloma subspecialty expertise is limited — this international training background provides important reassurance that their care will be informed by global best practice, not just local convention.
It also means Prof. Shi is well-positioned to communicate with and collaborate with international oncologists, facilitating the kind of cross-border care coordination that CMCS specializes in.
30 Years of Myeloma Expertise
Multiple myeloma is a disease where experience accumulates in ways that matter clinically. Recognizing the early signs of treatment-related toxicity, knowing when to push for more aggressive therapy versus when to de-escalate, understanding how to manage myeloma in the context of renal failure or cardiac amyloidosis, and knowing which patients are likely to benefit from transplantation versus novel agent-only approaches — these are judgments that improve with decades of subspecialty practice.
Prof. Shi's 30+ years of focused hematology experience, with a particular emphasis on plasma cell disorders, means that her clinical judgment is informed by a depth of pattern recognition that younger specialists cannot replicate. For patients with complex or atypical presentations, this experience is particularly valuable.
Novel Agents, Transplant, and CAR-T: A Complete Toolkit
Prof. Shi's practice encompasses the full spectrum of modern myeloma treatment modalities:
Novel Agent Combinations: The backbone of modern myeloma therapy involves combinations of proteasome inhibitors (bortezomib, carfilzomib, ixazomib), immunomodulatory drugs (thalidomide, lenalidomide, pomalidomide), and anti-CD38 monoclonal antibodies (daratumumab, isatuximab). Prof. Shi has extensive experience selecting and sequencing these agents based on patient-specific factors including cytogenetic risk, renal function, performance status, and prior treatment history.
Autologous Stem Cell Transplantation (ASCT): ASCT remains a standard of care for transplant-eligible newly diagnosed myeloma patients, deepening responses achieved with induction therapy and extending progression-free survival. Prof. Shi has performed ASCT throughout her career and is experienced in patient selection, conditioning regimen optimization, and post-transplant maintenance strategies.
CAR-T Cell Therapy: For patients with relapsed/refractory myeloma — particularly those who are triple-class refractory (refractory to a proteasome inhibitor, an IMiD, and an anti-CD38 antibody) — BCMA-targeted CAR-T therapy has produced remarkable response rates. China has approved multiple BCMA CAR-T products and has one of the world's largest clinical experiences with this modality. Oriental Hospital's hematology program has access to CAR-T therapy for eligible patients, and Prof. Shi's team can conduct eligibility assessments for international patients considering this option.
Oriental Hospital Shanghai: An Emerging Center of Excellence
Oriental Hospital Shanghai (affiliated with Tongji University) has developed a strong hematology program under Prof. Shi's leadership. As a large general hospital with comprehensive subspecialty support — including nephrology, cardiology, and infectious disease — it is well-equipped to manage the systemic complications that frequently accompany myeloma, including renal impairment, cardiac involvement in AL amyloidosis, and infection risk during immunosuppressive therapy.
Who Should Consider Consulting Prof. Shi Jumei
- Newly diagnosed myeloma patients seeking expert second opinion on induction regimen and transplant eligibility
- Relapsed or refractory myeloma patients who have progressed on standard therapies
- Triple-class refractory patients being evaluated for CAR-T therapy eligibility
- Patients with myeloma-related renal impairment or AL amyloidosis requiring integrated management
- Patients who have been treated at international centers and want a Chinese specialist with international training experience
- Patients seeking a second opinion on transplant timing or conditioning regimen selection
- Patients with high-risk cytogenetics requiring specialized treatment strategies
How CMCS Connects You with Prof. Shi Jumei
China Medical Concierge Shanghai (CMCS) facilitates access to Prof. Shi Jumei for international patients with multiple myeloma and related plasma cell disorders. Our team manages the full coordination process — from remote case review and medical record translation to appointment scheduling, interpretation, and in-hospital support.
To begin, patients or their families are encouraged to share available medical records including bone marrow biopsy and cytogenetics reports (FISH panel), M-protein quantification (SPEP, UPEP, serum free light chains), imaging studies (whole-body low-dose CT or PET-CT), renal function tests, and prior treatment summaries. Prof. Shi's team can conduct an initial remote assessment before any travel to Shanghai is required.
CMCS provides end-to-end support including:
- Medical record translation (English, Arabic, French, and other languages)
- Remote pre-consultation case review
- Appointment coordination with Prof. Shi Jumei's clinic at Oriental Hospital Shanghai
- On-site interpretation during consultations and procedures
- CAR-T therapy and stem cell transplant eligibility assessment
- Post-consultation summary and follow-up support
Contact CMCS to Connect with Prof. Shi Jumei
📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com
CMCS – China Medical Concierge Shanghai connects international patients with Shanghai's leading specialists. We are a health management company, not a hospital. All clinical decisions are made by the treating physician.
0件のコメント